Floatz logo

Daunorubicin

AML With Mutated NPM1

Shen yangPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the AML With Mutated NPM1 cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Shen yang
Phase 3B
Azacitidine
Shen yang
Phase 2B
Venetoclax
Kura Oncology, Inc.
Phase 2B
Arsenic Trioxide
The University of Hong Kong
Phase 2CCC
BN104
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1/2CC

View all 14 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →